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ABSTRACT 
Objective: To develop and validate a stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) assay for the 
determination of phenytoin in bulk and pharmaceutical dosage forms.  
Methods: A HPLC instrument incorporating aZorbaxC-18 analytical column (250x4.6 mm, 5μm particles) with a mobile phase comprising 
acetonitrile: water in the ratio 50:50 (%v/v) was employed for the determination of phenytoin. The flow rate was set with an isocratic program, the 
temperature of the column was maintained at 25 °C and a detection wavelength of 200 nm was employed using an ultraviolet detector. The method 
was validated as per The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) guidelines. 
Results: Total chromatographic analysis time per sample was 6 min with phenytoin eluting with the reaction time of 4.6±0.2 min. Phenytoin was 
exposed to acidic, basic, oxidative, photolytic and thermal stress conditions and the specificity of the assay was confirmed. The calibration plot was 
linear (R2≥0.999) over the phenytoin concentration range 5.0-100.0μg/ml. The percentage means recoveries were found to be in the range of 98-
102%. The relative standard deviation of precision and robustness were within prescribed limits (<2%). The limit of detection was 0.047 µg/ml 
while the limit of quantitation was established as 0.143 µg/ml. 
Conclusion: A simple, accurate, precise and stability-indicating RP-HPLC assay was successfully developed for the determination of phenytoin in 
bulk and dosage forms. Hence, this assay is useful for the analysis of phenytoin in formulations in medicines development and pharmaceutical 
manufacturing setting. 
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INTRODUCTION 
Phenytoin (5, 5-diphenylhydantoin or Dilantin) was first introduced 
as an anticonvulsant medication in 1937[1]. It helps to dampen the 
un wanted, runaway brain activity associated with seizures by 
stabilizing the inactive state of voltage-gated sodium channels, 
leading to a reduction in electrical conductance among brain cells. 
Phenytoin is a member of the family of phenyl hydantoins (fig. 1), 
exhibiting a pKa value of 8.3 and is practically insoluble in water [2]. 
Phenytoin is normally administered as a solid oral dosage form 
(capsules) in the treatment of epilepsy [3] and has been employed 
both topically and systemically in the treatment of lichen planus, 
epidermolysis bullosa and inflammatory conditions [4]. A number of 
studies have also shown that phenytoin has a positive effect on 
wound healing in a variety of cases including leg ulcers, leprosy 
wounds, burns and diabetic foot ulcers [4-7].  
Despite the proven clinical utility of phenytoin, there are relatively 
few analytical methods reported for the determination of phenytoin 
in bulk, in formulations and in blood plasma. These are generally 
based on thin layer chromatography, spectrophotometry, enzyme 
immunoassay, radioimmunoassay and liquid chromatography [8-13]. 
Athin layer chromatographic method was used to determine 
phenytoin in pharmaceutical formulations and identify its 
hydroxylated urinary metabolites [8]. A novel study reported the 
development of a liquid chromatography method coupled with 
electro spray ionization tandem mass spectrometry to detect and 
quantify phenytoin in human plasma [9]. Walash et al. (2011) 
developed a spectrophotometric method for detection and 
determination of trace impurities in phenytoin bulk powder and 
pharmaceutical formulations [10]. The quantitative assay of 
phenytoin in sera by various methods, such as spectrophotometry, gas 
chromatography, liquid chromatography, enzyme immunoassay and 
radioimmunoassay had been described [11]. Khe dr et al. (2008) 
reported a HPLC method for determination of phenytoin in rabbits 
receiving sildenafil [12]. Lin et al. (2010) measured free and total 
levels of phenytoin in human plasma collected from patients with 
epilepsy using micellar electro kinetic chromatography method [13]. 
However, the methods for quantitative determination of phenytoin in 
pharmaceutical formulations are very scarce in the scientific literature. 
Hence, the objective of this study was to develop a simple, specific, 
accurate, precise, sensitive and stability-indicating isocratic RP-
HPLC assay for the determination of phenytoin in bulk and 
pharmaceutical dosage forms. This method was validated in 
accordance with ICH guidelines [14-16]. 
MATERIALS AND METHODS 
Chemicals and reagents 
 
Fig. 1: Chemical structure of phenytoin 
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Phenytoin was purchased from Chemolab Sdn. Bhd. (Selangor, 
Malaysia). Phenytoin capsules were obtained from Pfizer Inc. (New 
York, United States). Acetonitrile of HPLC grade was purchased from 
Fisher Scientific Sdn. Bhd. (Selangor, Malaysia). Other chemicals of 
HPLC grade purity were purchased from commercial sources. Water 
was purified using Sartorius Ultrapure Water System (Goettingen, 
Germany).  
HPLC method and chromatographic conditions 
Chromatographic system and conditions 
Analysis of phenytoin in bulk (non-formulated powder) and in 
formulations was performed using a HPLC system (1200 series, 
Agilent Technologies) equipped with a pump, injector valve with 20 
µl sample loop, ZORBAX Eclipse Plus C-18 analytical column 
(250×4.6 mm, 5 μm particles) and ultraviolet (UV) detector with 
data processor (Chem Station Software). UV detection for phenytoin 
was set at 200 nm. The mobile phase acetonitrile: water (ACN: H2O) 
of 50:50 (%v/v)was delivered at ambient temperature (25±2 °C) at 
a flow rate of1.0 ml/min. Before analysis, the mobile phase was 
filtered through a 0.45 μm, 47 mm membrane filter (Membrane 
Solution, United States) and degassed in an ultrasonic bath (Fisher 
Scientific, Malaysia). The mobile phase was delivered by an isocratic 
method under RP-HPLC conditions and the system was equilibrated 
before each injection. 
Preparation of standard stock solution 
A standard stock solution was prepared by dissolving phenytoin 
powder (5 mg, accurately weighed) in 5 ml acetonitrile (final 
concentration 1 mg/ml). The prepared solution was retained in an 
ultrasonic bath for 30 min and filtered through a 0.22 µm, 13 mm 
syringe filter (Membrane Solution, United States). Standard 
calibration (or working solutions) was prepared by diluting aliquots 
of the stock solution to obtain concentrations ranging from 5-100 
µg/ml. 
Sample preparation from phenytoin labeled capsules 
The contents of ten capsules (30 mg phenytoin-labeled capsules) 
and five capsules (100 mg phenytoin-labeled capsules) were 
individually weighed. Acetonitrile (10 ml) was added to aportion of 
the powder, equivalent to 10 mg phenytoin, and the solution was 
retained in an ultrasonic bath for 30 min. An aliquot of this solution 
was diluted with acetonitrile to obtain a phenytoin concentration of 
50 µg/ml. The solutions were filtered through a 0.22 µm, 13 mm 
syringe filter (Membrane Solution, United States) before injection 
into the HPLC instrument. 
HPLC method development andoptimization 
Five different wavelengths of ultraviolet light (225, 220, 215, 201 
and 200 nm) were investigated in the development of the HPLC 
method suitable for analysis of phenytoin in bulk and in 
formulations. The effect of each wavelength on the peak area was 
examined. A range of acetonitrile: water mobile phase compositions 
were investigated, namely 60:40 55:45, 50:50, 45:55 and 40:60 
(%v/v). Final selection of the mobile phase composition was decided 
on the basis of time required for analysis, ease of preparation, the 
sensitivity and specificity of the assay. 
System suitability 
Testing was performed to ensure that the HPLC assay was suitable 
for the intended analysis. Ten samples of the standard solution 
containing phenytoin at 45 µg/ml were analyzed to determine the 
chromatographic parameters of peak area, retention time, capacity 
factor, tailing factor and number of theoretical plates. 
Method validation 
Specificity 
Specificity refers to the ability to measure the molecule of interest in 
the presence of other components that may exist in the sample. 
Interference with measurement of the molecule of interest may be 
occasioned by other active entities, excipients, impurities, and 
degradation products and must be eliminated to ensure that a peak 
response is only due to a single component. Specificity was assessed 
by analyzing non-formulated (bulk) phenytoin alone and phenytoin 
removed from the capsules. The specificity of the method and the 
stability-indicating potential were confirmed by analyzing samples 
of bulk and formulated phenytoin that had been subjected to forced 
degradation by exposure to sunlight, ultraviolet radiation, and heat, 
and hydrogen peroxide, acidic and basic conditions. The various 
stress conditions are presented in the table 1. All stress treatment 
was carried out at 25 °C apart from heat stress testing at 60 °C. 
Following treatment, phenytoin solutions were prepared of 
concentration 50 µg/ml and subsequently analyzed by HPLC. The 
analyte peak was evaluated both for peak purity and the potential 
peak interference. 
 
Table 1: Stress conditions applied prior to assay of phenytoin 
Stress type Condition Time (h) 
Photolytic degradation Sunlight 24  
Ultraviolet light 1  
Thermal 60 °C 24  
Oxidative 0.3% H2O2 24  
Acidic hydrolysis 0.1NHCl, pH 1 24  
Basic hydrolysis 0.1NNaOH, pH 13 24  
 
Linearity 
Calibration standards for phenytoin were prepared from stock 
solution (1 mg/ml) at concentrations of 5, 10, 15, 20, 40, 50, 60, 80 
and 100 μg/ml. A calibration plot was constructed of peak area 
against concentration.  
Limit of detection and limit of quantification  
The limit of detection (LOD) is the lowest detectable amount of 
analyte in a sample whereas the limit of quantification (LOQ) is the 
lowest amount of analyte in a sample that can be quantified. The 
LOD and LOQ were calculating dusing the following equations as per 








→ Eq. 2 
Where S is the slope of the calibration plot and σ is the standard 
deviation of the response for the blank samples. 
Accuracy 
Accuracy of measurement was established using a recovery (spiking) 
study, in which known amounts of phenytoin corresponding to five 
concentration levels (50%, 80%, 100%, 120% and 150%)of a 
reference concentration (50µg/ml) were injected into the HPLC 
instrument. The experiment was performed in triplicate. The 
measured concentration of phenytoin in the injected samples by 
HPLC analysis was determined by measuring the peak area and 
fitting these values to the linear equation of the peak area versus 
concentration calibration curve.  
The recovery, bias and RSD values were determined in order to 
ensure the accuracy of the assay. The recovery percentage and bias 
percentage were calculated for each concentration level using 
following equations:  
Siang et al. 










× 100	→ Eq. 4 
Where Ct  and Ca are theoretical concentration and the actual 
concentration of injected samples, respectively. 
Precision 
Precision was determined as both repeatability and intermediate 
precision, in accordance with ICH recommendations. Repeatability 
of measurements was determined as intra-day variation by 
analyzing samples within a day. Intermediate precision was 
determined by measurement of inter-day variation following a daily 
analysis of samples for three days. For both intra-day and inter-day 
precision, solutions of phenytoin (six samples) of concentration 50 
μg/ml were analyzed.  
Robustness 
The robustness of the developed method was investigated to assess 
the effect of small but deliberate variations of chromatographic 
conditions on the assay of phenytoin. Robustness was assessed by 
changing the flow rate (0.9 and 1.1 ml/min), the mobile phase 
composition (ACN: H2O=48:52% v/v and 52:48%v/v) and the 
column temperature (23 °C and 27 °C). 
Stability of the analytical solution 
The stability of phenytoin in solution during HPLC analysis was 
determined by repeated analysis of samples during the course of 
experimentation on the same day and also after storage of the drug 
solution for one week under ambient conditions (25±2 °C) and 
under refrigeration (4±2 °C) respectively. 
Application of the developed HPLC method to marketed 
formulations of phenytoin 
The HPLC method developed in this study was applied to estimate 
the phenytoin content of commercially available 30 mg phenytoin-
labeled capsules and 100 mg phenytoin-labeled capsules. 
RESULTS AND DISCUSSION 
HPLC method development and optimization 
In the development of analytical assays, optimal conditions are 
established based on speed, reliability and reproducibility. In this 
work, no internal standard was used because no extraction or 
separation step was involved. Prior knowledge of the UV absorption 
spectra of phenytoin assisted the initial development of the assay. 
The maximum absorption (peak area) of phenytoin in acetonitrile 
was previously reported as 200 nm [13]. The maximum absorption 
of a 20 µg/ml phenytoin solution in acetone in the present study also 
occurred at a wavelength (λmax) of 200 nm (table 2). In addition and 
as expected, the peak area was found to be affected by the 
wavelength used. 
 
Table 2: Peak area versus UV wavelength for phenytoin solutions using HPLC 
Sample Peak area  
225 nm 220 nm 215 nm 201 nm 200 nm 
1 649.60 1059.60 1639.50 3671.90 3894.50 
2 666.90 1054.80 1607.80 3603.10 3869.40 
3 652.90 1073.60 1636.90 3624.90 3964.20 
Mean 656.47 1062.67 1628.07 3633.30 3909.37 
SD 9.18 9.77 17.60 35.16 49.12 
RSD 1.40 0.92 1.08 0.97 1.26 
 
The results of the relationship between the composition of the 
mobile phase and the resulting chromatographic profiles for 
phenytoin assay are presented in table 3. Most compositions did not 
furnish sharp, well-defined peaks and either resulted in much lower 
sensitivity or did not give well-defined peaks in a short time scale. 
ACN: H2O ratio of 50:50 (%v/v) was found to furnish sharp, well-
defined peaks with the best symmetry (0.94) combined with lower 
tention time (4.6 min). Hence, the wavelength of 200 nm and the 
mobile phases ACN: H2O ratio of 50:50 (%v/v) were used in the 
present study. 
 
Table 3: The effect of mobile phase composition on HPLC assay of phenytoin 
Mobile phase composition (ACN: H2O) Retention time (min) Peak area Symmetry 
60:40 3.49 9425.47 0.91 
55:45 3.92 9300.83 0.88 
50:50 4.57 10014.50 0.94 
45:55 5.64 9610.13 0.79 
40:60 7.47 9590.23 0.73 
 
System suitability  
System suitability was evaluated by replicate injections (n=10) of a 
standard solution containing phenytoin at 45µg/ml. The results of 
retention time, peak area, capacity factor, tailing factor, and number 
of theoretical plates for the analyte are presented in Table 4. The 
RSD values of retention time and peak area were within 1%, 
indicating the suitability of the system. The capacity factor, USP 
tailing factor and the number of theoretical plates were within the 
acceptance criteria of>1, ≤1.5 and>2000, respectively [17]. These 
results thus indicated high efficiency and suitability of the developed 
HPLC system for the intended application. 
 
Table 4: Analysis of HPLC system suitability for the assay of phenytoin 
Properties Mean (n=10) RSD (%) 
Retention time  4.57 0.08 
Peak area 8947.34 0.98 
Capacity factor 3.59 0.13 
Tailing factor 0.79 1.39 
Number of theoretical plates 6152.70 1.43 
Method validation 
Specificity and forced degradation study 
 
Fig. 2: Typical HPLC chromatograms of standard (bulk) 
phenytoin (A) and phenytoin extracted from 
formulations (B) 
 
Fig. 3: Typical chromatograms of phenytoin 
to forced degradation (A) sunlight, UV light
temperature of 60 °C (B) oxidative condition(C) basic condition
(D) acidic condition 
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The specificity of the developed HPLC method was assessed by 
analyzing phenytoin in its non-
2A) and phenytoin extracted f
The peaks obtained were well resolved from the solvent front 
no interference was observed, indicating that the method was 
specific for phenytoin in bulk and in
The specificity and stability-indicating potential of the developed 
HPLC method was confirmed by exposing a solution of phenytoin 
to different stress conditions. The drug demonstrated relatively 
good stability under heat and photolytic (sunlight and UV light) 
conditions.  
The retention time and peak area of these chromatograms 
similar to untreated samples (
degrade under oxidative condition (
(fig. 3C) giving rise to small peaks at retention times of 2.3 min and 
2.2 min, respectively. The chromatogram of phenytoin
exposure to acidic condition
occurring at a retention time of 
In all forced degradation studies carried out in this study, there was 
no significant change in peak area and retention time of the active 
drug. The peaks of the degradation products were completely
resolved from the peaks for phenytoin and did not interfere with 
drug analysis. Thus, the developed method offers potential for the 
selective and specific determination of phenytoin in pharmaceutical 
formulations. 
 
Linearity & range 
 
Fig. 4: Linearity and range of 
assay of phenytoin
A standard curve for phenytoin 
the peak area versus drug concentration of phenytoin
concentration range of 5-100 µg
found to be 0.9997, which indicated
between the concentration of the analyte and the peak area. 
The calibration data, with their relative standard dev
are listed in table 5. The low values of RSD 
method is precise and the calibration plot 
linearity.
phenytoin solution using 
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Limit of detection and limit of quantification  
The LOD and LOQ of phenytoin in the mobile phase were determined to 
be 0.047 and 0.143 μg/ml, respectively. Both findings indicate that the 
developed method is sensitive and can be used for detection and 
quantification of phenytoin over a wide range of concentrations. 
Accuracy 
The percentage recovery of phenytoin at each concentration level 
(50%, 80%, 100%, 120% and 150%) is presented in table 6. The 
percentage recovery (measured amount relative to the actual 
injected amount) was within acceptable limits (100±2%). 
Furthermore, the bias and RSD were within±2%. All the results 
confirmed that the developed HPLC method was accurate for the 
determination of the phenytoin. 
Precision 
Repeatability of measurement was determined as intra-day 
variation while inter-mediate precision was determined by 
measuring inter-day variations for six samples of phenytoin at 50 
μg/ml. Repeatability and intermediate precision (table 7) were 
found to be within the limits prescribed in ICH guidelines (RSD<2%). 
 
Table 6: Accuracy of developed HPLC method for phenytoin 
Spike level 
(%) 
Concentration of drug added 
(µg/ml) 








50 25 24.96 99.85 0.34 1.37 0.15 
80 40 39.93 99.83 0.31 0.79 0.17 
100 50 49.94 99.89 0.43 0.86 0.11 
120 60 60.62 101.03 0.41 0.68 1.03 
150 75 75.02 100.03 0.92 1.22 0.03 
 
Table 7: Intra-day and inter-day precision of developed HPLC assay of phenytoin 
Sample Intra-day precision Inter-day precision 
Day 1 Day 2 Day 3 
Sample-1 10006.60 9934.10 9918.00  
Sample-2 9770.80 9967.30 10046.90 
Sample-3 9850.80 9927.70 9970.80 
Sample-4 10009.40 9951.60 10168.80 
Sample-5 9917.40 9880.60 10167.80 
Sample-6 9828.90 9918.40 10207.60 
Mean 9897.32 9929.95 10079.98 9969.08 
SD 97.73 29.85 119.28 97.42 
RSD (%) 0.99 0.30 1.18 0.98 
 
Robustness 
The robustness of the developed method was established by 
monitoring the influence of small changes in chromatographic 
conditions on peak area and retention time. No significant changes 
(table 8) in these parameters were detected (RSD<2%) when 
changes were made to the organic content of the mobile phase 
(±2%), temperature (±2 °C) and flow rate (±10%).  
Thus minor modifications to the experimental parameters do not 
affect the developed assay and its ability to accurately and precisely 
detect or quantify phenytoin. 
Solution stability 
The results presented in table 9 demonstrate that the analytical 
phenytoin solution (45 µg/ml) remains stable for one week at room 
temperature (25±2 °C) and during refrigeration (4±2 °C) 
respectively with no significant degradation. All RSD values were 
less than 2%. 
Assay of phenytoin content in capsule formulations 
The developed HPLC method was applied to measure the content of 
phenytoin in commercially available capsule formulations. The mean 
percentage recovery of phenytoin in 30 mg and 100 mg phenytoin-
labeled capsules was found to be 99.23±1.75%and 99.13±1.63% 
respectively, in close agreement with the labeled amounts. 
Corresponding RSD values are within the limits prescribed in ICH 
guidelines (RSD<2%).  
These findings suggest that the developed HPLC method is highly 
suitable for the accurate determination of phenytoin in 
pharmaceutical formulations. 
 
Table 8: The influence of changes in chromatographic parameters on HPLC analysis of phenytoin 
Parameters Modification Retention time (min) RSD (%) Peak area RSD (%) 
Normal condition - 4.58 0.07 9805.80 0.51 
Mobile phase composition, ACN: H2O(%v/v) 48:52 4.93 0.03 9816.20 0.46 
52:48 4.29 0.08 10000.27 0.53 
Temperature( °C) 23 4.53 0.12 9846.53 1.05 
27 4.50 0.01 9686.00 0.62 
Flow rate (ml/min) 0.9 5.09 0.03 11132.93 0.89 
1.1 4.14 0.47 9995.67 1.15 
Normal conditions: ACN: H2O=50:50 (%v/v); temperature 25 °C, Flow rate 1.0 ml/min. 
Table 9: Stability of phenytoin solutions revealed by the developed HPLC assay 
Storage conditions Freshly prepared phenytoin solution Phenytoin solution stored for one week 
Retention time (min) Peak area RSD (%) Retention time (min) Peak area RSD (%) 
25±2 °C 4.57 8939.17 0.66 4.56 8831.43 0.41 
4±2 °C     4.57 8908.97 1.22 
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CONCLUSION 
An isocratic RP-HPLC assay was developed for the determination of 
phenytoin and validated according to ICH guidelines. The method 
has been proven to be accurate, precise, reproducible, specific and 
stability-indicating. Furthermore, the assay utilizes an economical 
and readily available mobile phase and has been found to exhibit 
linearity between peak area and drug concentration over a wide 
concentration range. All these factors recommend the HPLC method 
for quantification of phenytoin in the bulk,non-formulated state and 
in pharmaceutical dosage forms.  
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